Dalfampridine
- Generic Name
- Dalfampridine
- Brand Names
- Ampyra, Fampyra, Fampridine Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C5H6N2
- CAS Number
- 504-24-5
- Unique Ingredient Identifier
- BH3B64OKL9
- Background
Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010.
- Indication
Dalfampridine is a neurofunctional modifier that helps improve walking speed in patients with multiple sclerosis (MS).
- Associated Conditions
- Multiple Sclerosis
- Associated Therapies
- -
4-aminopyridine for Skin Wound Healing
- Conditions
- Interventions
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- John Elfar
- Target Recruit Count
- 68
- Registration Number
- NCT06333171
- Locations
- 🇺🇸
University of Arizona, Tucson, Arizona, United States
4AP to Delay Carpal Tunnel Release (CTR)
- Conditions
- Interventions
- First Posted Date
- 2024-03-06
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- John Elfar
- Target Recruit Count
- 160
- Registration Number
- NCT06294821
4-AP Peripheral Nerve Crossover Trial
- Conditions
- Interventions
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- University of Arizona
- Target Recruit Count
- 68
- Registration Number
- NCT06003166
Effects of 4-AP on Functional SCI Recovery
- Conditions
- Interventions
- First Posted Date
- 2022-07-07
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Shirley Ryan AbilityLab
- Target Recruit Count
- 44
- Registration Number
- NCT05447676
- Locations
- 🇺🇸
Shirley Ryan Abilitylab, Chicago, Illinois, United States
A Single Dose Pharmaco-Diagnostic for Peripheral Nerve Continuity After Trauma
- First Posted Date
- 2019-07-19
- Last Posted Date
- 2022-10-18
- Lead Sponsor
- Milton S. Hershey Medical Center
- Target Recruit Count
- 1
- Registration Number
- NCT04026568
- Locations
- 🇺🇸
MS Hershey Medical Center, Hershey, Pennsylvania, United States
High Doses of 4-aminopyridine in Clinically Complete Chronic Spinal Cord Injury Patients.
- Conditions
- Interventions
- First Posted Date
- 2019-04-02
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Coordinación de Investigación en Salud, Mexico
- Target Recruit Count
- 150
- Registration Number
- NCT03899584
- Locations
- 🇲🇽
Hospital de Especialidades, CMN Siglo XXI, Mexico City, Mexico
Muscle Strain in Multiple Sclerosis Patients Measured by Ultrasound Speckle Tracking Technique
- First Posted Date
- 2019-02-20
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- University of Southern Denmark
- Target Recruit Count
- 48
- Registration Number
- NCT03847545
- Locations
- 🇩🇰
University of Southern Denmark - Odense Univarsity Hospital, Odense C, Denmark
4-aminopyridine Treatment for Nerve Injury
- Conditions
- Interventions
- First Posted Date
- 2018-10-10
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- John Elfar
- Target Recruit Count
- 70
- Registration Number
- NCT03701581
- Locations
- 🇺🇸
University of Arizona, Tucson, Arizona, United States
🇺🇸University of Rochester, Rochester, New York, United States
4-aminopyridine Treatment for Nerve Injury From Radical Retro-Pubic Prostatectomy
- First Posted Date
- 2018-09-05
- Last Posted Date
- 2018-11-02
- Lead Sponsor
- University of Rochester
- Registration Number
- NCT03658408
- Locations
- 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States
4-Aminopyridine, Atenolol, or Placebo in Patients With Vestibular Migraine
- Conditions
- Interventions
- First Posted Date
- 2018-07-06
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- Massachusetts Eye and Ear Infirmary
- Registration Number
- NCT03578354
- Locations
- 🇺🇸
Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.